Fresenius Medical Care (XTRA:FME) has triggered fresh attention after reshaping its China business by exiting peritoneal dialysis, discontinuing the locally produced 4008A system and booking about €110 million in one-time portfolio streamlining costs.
At a share price of €39.57, Fresenius Medical Care has seen short term momentum cool, with the 90 day share price return down 3.84% and the year to date move down 1.49%, while the 3 year total shareholder return of 11.59% contrasts with a 23.34% decline over five years. This suggests past progress but fading longer term momentum as investors reassess risk around portfolio changes such as the China restructuring.
Compare Fresenius Medical Care's refocus on higher value treatments with other healthcare stocks that screen strongly on balance sheet strength and fundamentals using our curated list of solid balance sheet and fundamentals (205 results)
Fresenius Medical Care now carries fresh China restructuring costs alongside solid reported revenue and profit figures. Does the current share price still compensate you enough for those risks on valuation grounds?
Most Popular Narrative: 99% Undervalued
Against a last close of €39.57, the most followed narrative pegs Fresenius Medical Care’s fair value at €7,750, which points to an extremely wide gap that only makes sense if long term earnings power and cash generation are being heavily underappreciated today.
The pipeline of novel therapies that delay or prevent the need for dialysis, such as emerging drugs, wearable artificial kidneys, or possible breakthroughs in kidney transplantation, threatens to structurally shrink demand for in-center and home dialysis, undermining long-term revenue stability and growth potential for Fresenius Medical Care.
See why 0 investors see Fresenius Medical Care as 99% undervalued.
Result: Fair Value of €7,750 (UNDERVALUED)
Still, Fresenius Medical Care could see this pessimistic story crack if Value-Based Care gains more traction or if cash generation continues to support sizeable buybacks.
Find out about the key risks to this Fresenius Medical Care narrative.
Next Steps
Mixed signals on Fresenius Medical Care so far. If you want to move quickly and form your own stance, start by weighing its 5 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Fresenius Medical Care?
If Fresenius Medical Care has caught your eye, do not stop there. Broaden your watchlist and pressure test your thesis against other carefully filtered opportunities.
- Target steadier compounding by reviewing companies that score well on resilience and fundamentals through our 224 resilient stocks with low risk scores.
- Pursue value-focused opportunities by scanning a curated set of attractively priced businesses with strong quality markers via the 191 high quality undervalued stocks.
- Hunt for high potential stories that are not widely followed yet by checking the 617 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com